Drugs / Clostridium difficile vaccine
Clostridium difficile vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02725437 | Feb 2016 → Feb 2017 | Clostridium difficile colitis | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00127803 | Jul 2005 → Jan 2006 | Clostridium difficile colitis | Sanofi | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02561195 | Jul 2015 → Mar 2017 | Clostridium difficile colitis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02117570 | Jul 2014 → Dec 2015 | Clostridium difficile colitis | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03579459 Comparator | Jul 2018 → Aug 2019 | Clostridium difficile colitis | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clostridium difficile Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02725437 ↗ |
| Known as | C difficile vaccine | “an investigational C difficile vaccine containing a mixture of genetically detoxified and chemically inactivated toxoids, A and B.” PMID 30962095 ↗ Apr 20191“Participants received C difficile vaccine (200 μg total toxoid) or placebo (Months 0, 1, 6).” PMID 37977942 ↗ Nov 2023 |
| Known as | Clostridium difficile toxoid vaccine | “Fifty healthy adult (18-55 years) and 48 elderly (≥ 65 years) volunteers were randomized to receive a candidate Clostridium difficile toxoid vaccine (2 μg, 10 μg, or 50 μg) or...” PMID 22306375 ↗ Feb 2012 |
| Known as | modified C. difficile vaccine | “The purpose of this study is to determine the safety and tolerability of a modified C. difficile vaccine at 3 dose levels compared with a placebo control administered via...” NCT00127803 ↗ |
| Modality | Vaccine | “Clostridium Difficile Toxoid Vaccine” NCT00127803 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscular on Days 0, 28, and 56, respectively.” NCT00127803 ↗ |